Life Biosciences has reported the first human data from a Phase 1 trial of ER-100, an AAV2-delivered gene therapy expressing three Yamanaka factors (OCT4, SOX2, KLF4) in the eye under doxycycline control. Across three patients with open-angle glaucoma at the starting dose, no serious adverse events or dose-limiting toxicities occurred through Day 56, and two participants showed early improvement on visual-field testing. Partial epigenetic reprogramming has moved from animal models into a controlled clinical question, with dose escalation now authorized.
Key Points
- First-in-human partial reprogramming trial completed initial dose cohort safely
- Two of three glaucoma patients showed early visual-field improvement
- Doxycycline-gated OSK expression omits c-MYC to limit cancer risk
Longevity Analysis
Restoring function to retinal ganglion cells — cells long considered irreversibly lost once damaged — tests whether epigenetic age reversal translates into recovered capability rather than cleaner biomarkers. The architecture of the trial is as instructive as the result: a tumor-associated factor removed, expression gated by an oral switch, inflammation from the viral vector damped with a tapering steroid course, each element designed to contain what reprogramming can do before asking what it can repair. Three patients and 56 days establish tolerability, not efficacy, and the functional signal warrants observation rather than conclusion.
Original published by Longevity.Technology, by Eleanor Garth.